论文部分内容阅读
为观察良、恶性乳腺疾病卵巢激素含量的变化，及其与免疫细胞化学测定结果之间可能存在的关系。对经病理确诊的107例病例（其中浸润性乳腺导管癌31例，纤维腺瘤49例及小叶增生27例）严格区对，检测了各组激素含量与免疫细胞化学抗体（抗细胞增殖抗原Ki67、抗肿瘤抑制基因P53蛋白产物、抗原癌基因C－erbB－2蛋白产物，抗雌激素受体、抗孕激素受体），并对测定结果进行对照。结果表明：浸润性导管癌和纤维腺瘤之间，总雌二醇（TE2）、游离雌二醇（FE2）含量均有极显著差异（P＜0．01），Pg也有显著性差异（P＜0．05）。浸润性导管癌与小叶增生之间，TE2有显著性差异（P＜0．05），FE2与Pg无明显差异（P＞0．05），而纤维脉瘤和小叶增生之间，TE2、FE2和Pg均无明显差异（P＞0．05）。提示雌激素含量可判别乳腺癌高危妇女，对这些妇女定期普查或用抗雌激素治疗可能可以预防乳腺癌的发生。对乳腺组织进行了细胞增殖抗原Ki67、肿瘤抑制基因P53、原癌基因C－erbB－2和激素受体ER、PR的检测，并与TE2、FE2和孕酮（Pg）进行比较。结果表明：浸润性导管癌P53与FE2含量差异有显著性，与TE2和Pg无明显差异（P＞0．05）。浸润性导管癌TE2、FE2和Pg与Ki67和C－erbB－2阳性与否差异无显著性。浸润性导管癌TE2、FE2和Pg?
In order to observe the changes of ovarian hormones in benign and malignant breast diseases and its possible relationship with the results of immunocytochemistry. Pathologically confirmed in 107 cases (including invasive ductal carcinoma in 31 cases, 49 cases of fibroadenoma and lobular hyperplasia in 27 cases) strict zone pairs of hormone levels and immunocytochemical antibodies (anti-cell proliferation antigen Ki67 , Anti-tumor suppressor gene P53 protein product, antigen oncogene C-erbB-2 protein product, anti-estrogen receptor, anti-progesterone receptor), and the results were compared. The results showed that the contents of total estradiol (TE2) and free estradiol (FE2) were significantly different between invasive ductal carcinoma and fibroadenoma (P <0.01) and Pg was also significantly different (P <0.05). Between invasive ductal carcinoma and lobular hyperplasia, there was a significant difference between TE2 and FE2 (P <0.05), but there was no significant difference between FE2 and Pg (P> 0.05) And Pg had no significant difference (P> 0.05). Prompt estrogen content can be identified in women at high risk of breast cancer, regular screening of these women or anti-estrogen therapy may be able to prevent the occurrence of breast cancer. The mammary gland tissues were tested for cell proliferation antigen Ki67, tumor suppressor gene P53, oncogene C-erbB-2 and hormone receptors ER and PR, and compared with TE2, FE2 and progesterone (Pg). The results showed that there was significant difference between P53 and FE2 in invasive ductal carcinoma, but no significant difference with TE2 and Pg (P> 0.05). The invasive ductal carcinoma TE2, FE2 and Pg and Ki67 and C-erbB-2 positive or not no significant difference. Infiltrating ductal carcinoma TE2, FE2 and Pg?